Antimicrobial agents for the dermatologist. I. β-Lactam antibiotics and related compounds

Journal of the American Academy of Dermatology

Volumn 37, Issue 2 I, 1997, Pages 149-165

  Epstein, M E ^a   Amodio Groton, M ^a   Sadick, N S ^a  

^a FACP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; AZLOCILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BIOCEF; CARBAPENEM DERIVATIVE; CARINDACILLIN; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFALOTIN; CEFAMANDOLE NAFATE; CEFAPIRIN; CEFAZOLIN; CEFEPIME; CEFIXIME; CEFONICID; CEFOPERAZONE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPODOXIME PROXETIL; CEFPROZIL; CEFRADINE; CEFTAZIDIME; CEFTIBUTEN; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DEMECLOCYCLINE; DIRITHROMYCIN; DOXYCAPS; DOXYCYCLINE; DOXYX; FANSIDAR; FOLIC ACID ANTAGONIST; FOSFOMYCIN TROMETAMOL; G MYCEN; GENTAMICIN; KANAMYCIN; KEFLAB; KLEBELL; LEVOFLOXACIN; LOMEFLOXACIN; LORACARBEF; MACROLIDE; MEROPENEM; METACYCLINE; METRONIDAZOLE; MEZLOCILLIN; MINOCYCLINE; MONOBACTAM DERIVATIVE; NAFCILLIN; NALIDIXIC ACID; NEO FRADIN; NEO TABS; NEOMYCIN; NETILMICIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; OXYTETRACYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PIPRAL; POLYMAX; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMYCIN; SALAZOSULFAPYRIDINE; SPARFLOXACIN; SPECTINOMYCIN; SULFAFURAZOLE; SULFAMETHIZOLE; SULFAMETHOXAZOLE; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; TIMENTIN; TOBRAMYCIN SULFATE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREIDOPENICILLIN DERIVATIVE; UROBIOTIC; VANOCIN; VANPEN; VIBRATALS;

ANTIMICROBIAL ACTIVITY; BACTERIAL SKIN DISEASE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE;

EID: 0030744882     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(97)80118-1     Document Type: Article

References (143)

1. LA. Duhring A practical treatise on diseases of the skin 1982 JB Lippincott Philadelphia 288 304
2. EP. Abraham Cephalosporins 1945—1986 JD Williams The cephalosporin antibiotics. 1987 Adis Press Auckland 1 14
3. EP Abraham PB. Loder Cephalosporin C EH Flynn Cephalosporins and penicillins: chemistry and biology. 1972 Academic Press New York 2 26
4. HC. Neu The new beta-lactamase-stable cephalosporins Ann Intern Med 97 1982 408 419
5. MD. Goldberg The cephalosporins Med Clin North Am 71 1987 1113 1133
6. GR Donowitz GL. Mandell Beta-lactam antibiotics. Part 2 N Engl J Med 318 1988 490 500
7. RC Moellering Jr MN. Swartz The new cephalosporins N Engl J Med 294 1976 24 28
8. EL Quinn D Pohlod T Madhavan Clinical experience with cefazolin and other cephalosporins in bacterial endocarditis J Infect Dis 128 Suppl 1983 386 391
9. LD Sabbath C Wilcox C Garner In vitro activity of cefazolin against recent clinical bacterial isolates J Infect Dis 128 Suppl 1973 320 326
10. GH Cuchural Jr FP Tally NV Jacobus Comparative activities of newer β-lactam agents against members of the Bacteroides fragilis group Antimicrob Agents Chemother 34 1990 479 480
11. C Morel M Vergnaud MM Langeard Cefotetan: comparative study in vitro against 266 gram-negative clinical isolates J Antimicrob Chemother 11 Suppl A 1983 31 36
12. CE Cherubin RHK Eng R Norrby Penetration of newer cephalosporins into cerebrospinal fluid Rev Infect Dis 11 1989 526 548
13. CA Gustaferro JM. Steckelberg Cephalosporin antimicrobial agents and related compounds Mayo Clin Proc 66 1991 1064 1073
14. JR Lonks AA. Medeiros The growing threat of antibiotic-resistant Streptococcus pneumoniae Med Clin North Am 79 1995 523 535
15. BA Cunha MV. Gill Cefepime Med Clin North Am 79 1995 721 732
16. JW Chow MJ Fine DM Schlaes Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy Ann Intern Med 115 1991 585 590
17. M Fassberder H Lode T Schaberg Pharmacokinetics of new oral cephalosporins, including a new carbacephem Clin Infect Dis 16 1993 646 653
18. RS Griffith HR. Black Cephalothin, a new antibiotic JAMA 189 1964 823 828
19. JD. Johnson The cephalosporins in dermatologic practice Int J Dermatol 25 1986 427 430
20. LC Parish JA. Witkowski Cephalosporin therapy in dermatologic practice Clin Dermatol 9 1992 459 469
21. CW Derrick K. Reilly The role of cephalexin in the treatment of skin and soft tissue infections Postgrad Med J 59 Suppl 5 1983 43 46
22. LC Parish DM Cocchetto K Werner Cefuroxime axetil in the treatment of cutaneous infections Int J Dermatol 6 1987 389 393
23. DL Stevens F Pein M. Drehobl Comparison of oral cefpodixime proxetil and cefaclor in the treatment of skin and soft tissue infections Diagn Microbiol Infect Dis 16 1993 123 129
24. J McCarty GE. Ruoff Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin structure infections in an adult population Am J Med 92 Suppl 6A 1992 80 85
25. RB Nadelman SW Luger E Frank Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease Ann Intern Med 117 1992 273 280
26. FM Gordin CB Wofsy J. Mills Once-daily ceftriaxone for skin and soft tissue infections Antimicrob Agent Chemother 27 1985 648 649
27. LC Parish DL. Jungkind Systemic antimicrobial therapy for skin and skin structure infections: comparison of fleroxacin and ceftazidime Am J Med 94 Suppl 3A 1993 166 173
28. R. Finch Treatment of respiratory tract infections with cephalosporin antibiotic Drugs 34 1987 180 204
29. JD. Klein Microbiologic efficacy of antibacterial drugs for acute otitis media Pediatr Infect Dis J 12 1993 973 975
30. SE Wilson JA Boswick RJ Duma Cephalosporin therapy in intra-abdominal infections: a multicenter randomized, comparative study of cefotetan, moxalactam and cefoxitin Am J Surg 155 1988 61 66
31. JS Moran WC. Levin Drugs of choice for the treatment of uncomplicated gonococcal infections Clin Infect Dis 20 1995 547 565
32. SR. Norrby Role of cephalosporins in the treatment of bacterial meningitis in adults: overview with special emphasis on ceftazidime Am J Med Suppl 2A 1985 56 61
33. Antimicrobial prophylaxis in surgery Med Lett 37 1995 79 82
34. M Evans AV. Pollock Trials on trials: a review of trials of antibiotic prophylaxis Arch Surg 119 1984 109 113
35. P Francioli J Etienne R Horgue Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks: efficacy and outpatient treatment feasibility JAMA 267 1992 264 267
36. MK Buening JS Wold KS Israel Disulfiram-like reactions to β-lactams [letter] JAMA 245 1981 2027
37. JC Wade CR Smith BG Petty Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside Lancet 2 1978 604 606
38. ML Hyneck RR Berardi RM. Johnson Interference of cephalosporins and cefoxitin with serum creatinine determination Am J Hosp Pharm 38 1981 1348 1352
39. AE Brown O Quesda D. Armstrong Minimal nephrotoxicity with cephalosporin aminoglycoside combinations in patients with neoplastic disease Antimicrob Agents Chemother 21 1982 592 594
40. AJ Lopez P O’Keefe M Morrissey Ceftriaxone-induced cholelithiasis Ann Intern Med 115 1991 712 714
41. BB. Levine Antigenicity and cross reactivity of penicillins and cephalosporins J Infect Dis 128 1973 364 366
42. NF Adkinson Jr A Saxon MR Spence Cross allergenicity and immunogenicity of aztreonam Rev Infect Dis 74 1985 613 621
43. A Saxon GN Beall AS Rohr Immediate hypersensitivity reactions to beta-lactam antibiotics Ann Intern Med 107 1987 204 215
44. RD Reynolds LC Grammer DK. Kelsey Cefaclor and serum sickness-like reactions JAMA 276 1996 950 951
45. SR. Norrby Side effects of cephalosporins Drugs 34 1987 105 120
46. HR Gralnick M McGinnis W Elton P. McCurdy Hemolytic anemia associated with cephalothin JAMA 217 1971 1193 1197
47. N Sang RB. Kammer Hematologic complications associated with β-lactam antibiotics Rev Infect Dis 5 1983 380 393
48. RJ Fass RL Perkins S. Saslaw Cephalexin: a new oral cephalosporin: clinical evaluation in sixty-three patients Am J Med Sci 259 1970 187 200
49. RDG. Cooper The carbacephems: a new beta-lactam antibiotic class Am J Med Suppl 6A 1992 2 6
50. SL. Barriere Pharmacology and pharmacokinetics of cefprozil Clin Infect Dis 14 Suppl 2 1992 S184 S188
51. D Sommers M Van Wyk PEO Williams Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing Antimicrob Agents Chemother 25 1984 344 347
52. HH Handfield WM McCormack EW Hook III A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea N Engl J Med 325 1991 1337 1341
53. Cefpodoxime proxetil: a new oral cephalosporin Med Lett 34 1992 884
54. Ceftibuten: a new oral cephalosporin Med Lett 38 1996 23 24
55. WE Sanders Jr CC. Sanders Inducible β-lactamases: clinical and epidemiologic implications for use of newer cephalosporins Rev Infect Dis 10 1988 830 838
56. A Ward DM. Richards Cefotetan: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use Drugs 30 1985 382 426
57. D Rahn S. Malawista Lyme disease: recommendations for diagnosis and treatment Ann Intern Med 114 1991 472 481
58. C. Thornsberry Review of in-vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria Am J Med 79 Suppl 2A 1985 14 20
59. CC. Sanders Cefepime: The next generation? Clin Infect Dis 17 1993 369 379
60. EP Abraham E. Chain An enzyme from bacteria able to destroy penicillin [letter] Nature 146 1940 837
61. CC Sanders WE. Sanders Emergence of resistance during therapy with the newer beta-lactam antiboitics: role of inducible beta-lactamases and implications for the future Rev Infect Dis 5 1983 639 648
62. F Lindberg S. Normark Contribution of chromosomal beta-lactamase to beta-lactam resistance in enterobacteria Rev Infect Dis 8 Suppl 3 1986 292 304
63. HC. Neu Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases Am J Med 79 Suppl 5B 1985 2 12
64. JW Sensakovic LG. Smith Beta-lactamase inhibitor combinations Med Clin North Am 79 1995 695 704
65. AR English JA Retsema AE Girard CP-45 899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization Antimicrob Agents Chemother 14 1978 414 419
66. V Frank FD. Daschner In vitro activity of sulbactam plus ampicillin against hospital isolates of coagulase-negative staphylococci and Acinetobacter species Infection 17 1989 272 274
67. GA Jacoby L. Sutton Pseudomonas cepacia susceptibility to sulbactam Antimicrob Agents Chemother 33 1989 583 584
68. MS. Maddux Effects of beta-lactamase-medicated antimicrobial resistance: the role of beta-lactamase inhibitors Pharmacotherapy 11 Suppl 1991 40S 50S
69. CC Knapp J Sierra-Madero JA. Washington Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830;CL 298,741) against clinical isolates and against mutants for Class 1 beta-lactamase Diagn Microb Infect Dis 12 1989 511 515
70. RT Fass RB. Prier Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate Antimicrob Agents Chemother 33 1989 1268 1274
71. GE Stein MJ. Gurwith Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination Clin Pharm 3 1984 591 599
72. DH Staniforth KJ Lilystone D. Jackson Effect of food on the bioavailability and tolerance of clavulanic acid/amoxicillin combination J Antimicrob Chemother 10 1982 131 139
73. RM Brown R Wise JM Andrew Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration Antimicrob Agents Chemother 21 1982 565 567
74. F Sorgel M. Kinzig The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam J Antimicrob Chemother 31 Suppl A 1993 39 60
75. GL Jungbluth DL Cooper GD Doyle Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function Antimicrob Agents Chemother 30 1986 896 900
76. N Wright R. Wise The elimination of sulbactam alone and combined with ampicillin in patients with renal dysfunction J Antimicrob Chemother 11 1983 583 587
77. CA Johnson CE Halstenson JS Kelloway Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease Clin Pharmacol Ther 51 1992 32 41
78. EJC Goldstein JF Reinhart PM Murray Outpatient therapy of bite wounds: demographic data, bacteriology and a prospective, randomized trial of amoxicillin-clavulanic acid versus penicillin ± dicloxacillin Int J Dermatol 26 1987 123 131
79. JS Tan RM Wishnow DA Talan The piperacillin-tazobactam skin and skin structure study group: treatment of hospitalized patients with complicated skin and skin structure infetions: double-blind, randomized multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate Antimicrob Agents Chemother 37 1993 1580 1586
80. JM Benson MC. Nahata Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination Drug Intell Clin Pharm 22 1988 534 541
81. L Less JA Milson AK Knirsch Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use Rev Infect Dis 8 Suppl 5 1986 S644 S650
82. PR Meylan T Calandra PA Casey Clinical experience with timentin in severe hospital infections J Antimicrob Chemother 17 Suppl C 1986 127 139
83. HM Bryson RN. Brogden Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential Drugs 47 1994 506 535
84. A Micozzi M Nucci M Venditti Piperacillin/tazobactam/amikacin versus piperacillin/ amikacin/teicoplanin in the empirical treatment of neutropenic patients Eur J Clin Microbiol Infect Dis 12 1993 1 8
85. DH Staniforth D Jackson HL Clarke Amoxicillin/clavulanic acid: the effect of probenecid J Antimicrob Chemother 12 1983 273 275
86. D Ganes V Batra K Faulkner Effect of probenecid on the pharmacokinetics of piperacillin and tazobactam in healthy volunteers Proceedings of the Sixth Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Washington, DC 1991 S299 Abstract PPDM8293. Pharmaceutical Research 8
87. D Jick JB. Porter Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia J Clin Pharmacol 21 1981 456 458
88. AP Ball S Mehtar A. Watson Clinical efficacy and tolerance of augmentin in soft tissue infection J Antimicrob Chemother 10 1982 67 74
89. CH Brown EA Natelson MW Bradshaw Study of the effects of ticarcillin on blood coagulation and platelet function Antimicrob Agents Chemother 7 1975 652 657
90. R Hochman J Clark A Rolla Bleeding in patients with infections Arch Intern Med 142 1982 1440 1442
91. LO. Gentry Effects of sodium piperacillin on platelet function in normal volunteers Antimicrob Agents Chemother 19 1981 532 533
92. GS Itokazu LH. Danziger Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy Pharmacotherapy 11 1991 382 414
93. WC Hellinger NS. Brewer Imipenem Mayo Clin Proc 66 1991 1074 1081
94. SR. Norrby Carbapenems Med Clin North Am 79 1995 745 759
95. RN. Jones Review of the in vitro spectrum of activity of imipenem Am J Med 78 1985 22 32
96. HC Neu P. Labthavikul Comparative in vitro activity of N-formimidoyl thienamycin against gram positive and gram negative aerobic and anaerobic species and its beta-lactamase stability Antimicrob Agents Chemother 21 1982 180 187
97. JP Quinn AE Studemeister CA DiVincenzo SA. Lerner Resistance to imipenem in Pseudomonas aeruginosa : clinical experience and biochemical mechanisms Rev Infect Dis 10 1988 892 898
98. DE Sentochnick GM Eliopoulos MJ Ferraro RC. Moellering Comparative in vitro activity of SM7338: a new carbapenem antimicrobial agent Antimicrob Agents Chemother 33 1989 1232 1236
99. W Sheikh DH Pitkin H. Nadler Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers Clin Infect Dis 16 Suppl 4 1993 S361 S366
100. B Lipman HC. Neu Imipenem: a new carbapenem antibiotic Med Clin North Am 72 1988 567 569
101. JD. Sobel Imipenem and aztreonam Infect Dis Clin North Am 3 1989 613 624
102. M. Barza Imipenem: first of a new class of beta-lactam antibiotic Ann Intern Med 103 1985 552 560
103. SR Norrby B Bjornegard F Ferber KH. Jones Pharmacokinetics of imipenem in healthy volunteers J Antimicrob Chemother 12 1983 109 124
104. GL Drusano M. Hutchison The pharmacokinetics of meropenem Scand J Infect Dis 96 1995 11 16
105. HH Liu NK Bolash ME McAnany RA. Lynch Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem-cilastatin, ciprofloxacin and ofloxacin Drug 49 Suppl 2 1995 215 218
106. RL. Marrier Role of imipenem/cilastatin in the treatment of soft tissue infections Am J Med 79 1985 140 144
107. IM Gould M Hudson J Morris Imipenem versus standard therapy in the treatment of serious soft tissue infections Drugs Exp Clin Res 14 1988 555 558
108. GB Calandra W Raupp KR. Brown Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetes Scand J Infect Dis 52 Suppl 1 1987 15 19
109. RJ Fass EH Freimer RV. McCloskey Treatment of skin and soft tissue infections with imipenem/cilastatin Am J Med 78 6 A 1985 110 112
110. RL Nichols JN Smith RN Geckler SE. Nilson Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections South Med J 88 1995 397 404
111. L Kager CE. Nord Inipenem/cilastatin in the treatment of intra-abdominal infections: a review of worldwide experience Rev Infect Dis 7 1985 518 521
112. RA Salata RL Gebhart DL Palmer Pneumonia treated with imipenem/cilastatin Am J Med 78 Suppl 6A 1985 104 109
113. R Liang R Yung E Chiu Ceftazidime verus imipenem/cilastatin as initial monotherapy for febrile neutropenic patients Antimicrob Agents Chemother 34 1990 1336 1341
114. DM Livermore Y-J. Yang β-Lactamase lability and inducer power of newer β-lactamase antibiotics in relation to their activity against β-lactamase inducibility mutants of Pseudomonas aeruginosa J Infect Dis 155 1987 775 782
115. RHK Eng AN Munsif BG Yangco Seizure propensity with imipenem Arch Intern Med 149 1989 1881 1883
116. GB Calandia E Lyndick J Carrigan Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin Am J Med 84 1988 911 918
117. GB. Calandia Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin Am J Med 78 Suppl 6A 1985 73 78
118. A Saxon GN Beall AS Rohr DC Adelman Immediate hypersensitivity reactions to beta-lactam antibiotics. UCLA Conference (moderator) (discussants) Ann Intern Med 107 1987 204 215
119. Imipenem AHFS Drug Information 95 1995 American Society of Health System Pharmacists Bethesda (MD) 191 199
120. NS Brewer WC. Hellinger The monobactams Mayo Clin Proc 66 1991 1152 1157
121. RB Sykes DP. Bonner Aztreonam: the first monobactam Am J Med 78 1985 2 10
122. LB Rice SM. Eliopoulos Imipenem and aztreonam: current role in antimicrobial therapy Curr Clin Top Infect Dis 10 1989 109 139
123. NH Georgopapadakou SA Smith B. Sykes Modes of action of aztreonam Antimicrob Agents Chemother 21 1982 950 956
124. NH Georgopapadakou SA Smith CM Cimarusti Binding of monobactams to penicillin binding proteins of Escherichia coli and Staphylococcus aureus : relation to antibacterial activity Antimicrob Agents Chemother 23 1983 98 104
125. HC. Neu Aztreonam: the first monobactam Med Clin North Am 72 1988 555 566
126. AL Barry C Thomsberry RN Jones TL. Gavan Aztreonam: antibacterial activity, β-lactamase stability, and interpretive standards and quality control guidelines for disk diffusion susceptibility tests Rev Infect Dis 7 Suppl 4 1985 594 604
127. HR Stutman DF Welch RK Schribnere MI. Marko In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients Antimicrob Agents Chemother 25 1984 212 215
128. MA Buesing JH. Jorgensen In vitro activity of aztreonam in combination with newer β-lactams and amikacin against multiply resistant bacilli Antimicrob Agents Chemother 25 1984 283 285
129. A Saxon EA Swabb NF. Adkinson Investigation into the immunologic cross- reactivity of aztreonam with other beta-lactam antibiotics Am J Med 78 Suppl 2A 1985 19 26
130. EA Swabb AA Sugarman M. Stern Oral bioavailability of the monobactam aztreonam (SQ 26,776) in healthy subjects Antimicrob Agents Chemother 23 1983 548 550
131. EA. Swabb Clinical pharmacology of aztreonam in healthy recipients and patients: a review Rev Infect Dis 7 Suppl 4 1985 605 612
132. SJ. Childs Aztreonam in the treatment of urinary tract infection Am J Med 78 1985 44 46
133. JR Rodriguez CH. Ramirez-Ronda Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections Am J Med J Med 78 Suppl 2A 1985 42 43
134. WJ Simmons JJ. Lee Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli Rev Infect Dis 7 1985 783 788
135. BE Scully SA. Henry Clinical experience with aztreonam in the treatment of gram-negative bacteremia Rev Infect Dis 7 Suppl 4 1985 789 793
136. JC Pastorek II C Cole KE Aldridge JC. Crapanzano Aztreonam plus clindamycin as therapy for pelvic infections in women Am J Med 78 Suppl 2A 1985 47 50
137. PG Jones KVI Rolston V Fainstein Aztreonam therapy in neutropenic patients with cancer Am J Med 81 1986 243 248
138. HL Dupont CD Ericsson JJ Mathewson Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in U.S. travelers to Mexico JAMA 267 1992 1932 1935
139. NF Adkinson Jr A Saxon MR Spence Cross allergenicity and immunodeficiency to aztreonam Rev Infect Dis 7 Suppl 4 1985 613 621
140. RB Moss E McClelland RP Williams Evaluation of the immunologic cross-reactivity of aztreonam in patients with cystic fibrosis who are allergic to penicillin and/or cephalosporin antibiotics Rev Infect Dis 13 1991 598 607
141. BJ McDonald JW Singer JA. Bianco Toxic epidermal necrolysis possibly linked to aztreonam in bone marrow transplant patients Ann Pharmacother 26 1992 34 35
142. Aztreonam. AHFS Drug Information 95. American Society of Health System Pharmacists 95:170-8.
143. JS Gerig ND Bolton EA Swabb Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics Kidney 28 1984 308 318